The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Detection of copy number aberrations in cholangiocarcinoma using shallow whole genome sequencing of plasma DNA.
 
Maria Farooq
No Relationships to Disclose
 
Jan B. Egan
No Relationships to Disclose
 
Bradon McDonald
No Relationships to Disclose
 
Havell Markus
No Relationships to Disclose
 
Tania Contente-Cuomo
No Relationships to Disclose
 
Martin Fernandez-Zapico
No Relationships to Disclose
 
George Vasmatzis
No Relationships to Disclose
 
Esteban Braggio
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun BioPharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Muhammed Murtaza
Patents, Royalties, Other Intellectual Property - Inivata